Royalty Pharma plc (NASDAQ:RPRX) Holdings Trimmed by Captrust Financial Advisors

Captrust Financial Advisors reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,829 shares of the biopharmaceutical company's stock after selling 14,499 shares during the quarter. Captrust Financial Advisors' holdings in Royalty Pharma were worth $378,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its position in Royalty Pharma by 4.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock valued at $79,888,000 after buying an additional 130,025 shares during the period. Jupiter Asset Management Ltd. acquired a new position in shares of Royalty Pharma in the 4th quarter valued at about $4,950,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Royalty Pharma by 303.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock valued at $13,926,000 after purchasing an additional 406,123 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Royalty Pharma by 9.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 94,208 shares of the biopharmaceutical company's stock worth $2,403,000 after purchasing an additional 8,018 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Royalty Pharma during the fourth quarter worth approximately $486,000. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Performance

RPRX stock opened at $34.25 on Tuesday. The firm has a 50 day moving average of $32.42 and a two-hundred day moving average of $30.06. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.32. The company has a market capitalization of $19.74 billion, a price-to-earnings ratio of 23.62, a P/E/G ratio of 2.31 and a beta of 0.49. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The firm had revenue of $839.00 million during the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $0.22 per share. The ex-dividend date is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.57%. Royalty Pharma's dividend payout ratio (DPR) is presently 47.57%.

Analyst Ratings Changes

RPRX has been the topic of several research reports. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Monday, May 12th. Finally, Morgan Stanley started coverage on Royalty Pharma in a report on Friday. They set an "overweight" rating and a $51.00 price objective for the company. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Royalty Pharma has a consensus rating of "Buy" and a consensus target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.